WHO ICTRP trial
A Randomized, Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) versus…
NL-OMON39162 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON39162 |
|---|---|
| Public title | A Randomized, Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy. |
| Scientific title | A Randomized, Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy. - CA209-037 |
| Primary sponsor | Bristol-Myers Squibb |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Belgium;Brazil;Canada;Denmark;France;Germany;Israel;Italy;Netherlands ;Norway;Spain;Sweden;Switzerland;United Kingdom;United States of America |
| Conditions | Advanced (Unresectable or Metastatic) Melanoma;10040900;Advanced (Unresectable or Metastatic) Melanoma |
| Interventions | The medical interventions for this trial include both BMS-936558 and Investigator*s choice (dacarbazine and carboplatin/paclitaxel). All compounds will be supplied by the Sponsor company. BMS-936558 or Investigator*s choice will be… |
| Registration date | Jan 30, 2014 |
| Target size | 12 |
| Secondary IDs | 2012-001828-35;NCT01721746;NL41284.031.12 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: